Alesi Surgical has secured approval from the US Food and Drug Administration for its Ultravision system.

By using electrostatic technology, the Ultravision system will clear the vapour and particulate matter generated by modern surgical cutting instruments during abdominal keyhole (laparoscopic) surgery.

The system can produce a small and low-energy electrostatic charge similar to the principal of static electricity, enabling surgeons to actively get rid of surgical smoke.

 When creating a working space inside the abdomen, the surgical device will also minimise the amount of cold and dry carbon dioxide gas.

Alesi Surgical managing director Dr Dominic Griffiths said: “We are thrilled to have gained FDA approval for our Ultravision system that will now allow us to enter the US market.

“Commercially the US represents approximately fifty per cent of the global medical device market and so it is difficult to overstate the importance of this for the company.”

 “Gaining FDA approval for Ultravision allows us to continue the progress and development in the US market.”

In 2009, Alesi Surgical was established as a spin out from the Cardiff University’s Welsh Institute of Minimally Invasive Surgery.

Until now, the firm has received around £6.1m venture capital funding from its investors IP Group and Finance Wales.

Finance Wales’ Phil Barnes said: “We are delighted with the progress Alesi is making and gaining this FDA clearance provides a cornerstone for their future success.”